A cross-sectional structured survey of patients receiving botulinum toxin type A treatment for blepharospasm
Autor: | Thomas R. Hedges, John Fezza, Amit Verma, Julie A. Woodward, Daniel D. Truong, John Burns |
---|---|
Rok vydání: | 2016 |
Předmět: |
Male
Time Factors Blepharospasm 030230 surgery Severity of Illness Index Disability Evaluation 030207 dermatology & venereal diseases 0302 clinical medicine Medicine Cervical dystonia Botulinum Toxins Type A Aged 80 and over Botox IncobotulinumtoxinA AbobotulinumtoxinA Middle Aged Treatment efficacy Treatment Outcome Neuromuscular Agents Neurology Patient Satisfaction Female medicine.symptom Psychology Adult Automobile Driving medicine.medical_specialty Clinical Neurology Survey result Dysport Drug Administration Schedule 03 medical and health sciences Rating scale Internal medicine OnabotulinumtoxinA Humans Xeomin Aged Botulinum Neurotoxin Type A business.industry medicine.disease Dermatology Cross-Sectional Studies Reading Time course 030221 ophthalmology & optometry Physical therapy Neurology (clinical) Geriatrics and Gerontology business 030217 neurology & neurosurgery Botulinum toxin type |
Zdroj: | Parkinsonism & Related Disorders. 22:e138 |
ISSN: | 1353-8020 |
Popis: | To characterize satisfaction with current standard-of-care botulinum neurotoxin type A (BoNT/A) treatment for blepharospasm, we performed a cross-sectional, structured survey in subjects with blepharospasm who had received ≥2 BoNT/A cycles. Subjects were interviewed immediately before re-injection to evaluate treatment satisfaction, time course of treatment effects, preferred injection intervals, Jankovic Rating Scale (JRS), and Blepharospasm Disability Index (BSDI).Subjects’ (n=114) last treatment was onabotulinumtoxinA (n=78), incobotulinumtoxinA (n=35), or abobotulinumtoxinA (n=1). The most frequent injection interval was 12weeks (46.5% subjects); 30.7% had an interval >12weeks. The main rationale for interval choice was “to maintain treatment efficacy” (44.7%). However, 36.6% reported that treatment effects usually declined within 8weeks; 69.6% within 10weeks. JRS and BSDI scores indicated re-emergence of symptoms before re-injection, with 70.2% and 73.7% of subjects reporting difficulties to drive and read, respectively. Overall, treatment satisfaction was high, but declined at the end of the cycle. Many subjects (52.3%) would prefer an injection interval of |
Databáze: | OpenAIRE |
Externí odkaz: |